GlobeNewswire

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
19/12/2025
Company announcement – No. 26 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, [...]
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
19/12/2025
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of SEQUOIA-HCM MYQORZO is Company’s First FDA-Approved Medicine Company [...]
U.S. FDA approves JASCAYD® (nerandomilast) tablets for the treatment of progressive pulmonary fibrosis in adults
19/12/2025
Not intended for UK audiences Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function. 1 , 2 Affecting up to 100,000 people in the U.S. and [...]
Third-Party Recognition Underscores Genesis Healthcare’s Ongoing Commitment to Excellence in Skilled Nursing Care
19/12/2025
KENNETT SQUARE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genesis Healthcare, Inc. (Genesis) today announced that multiple of its affiliated skilled nursing facilities have earned national recognition from U.S. News & [...]
Novartis and US government reach agreement on lowering drug prices in the US
19/12/2025
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricing Additional Novartis medicines will be made available through direct-to-patient platforms in 2026 Company remains committed [...]
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation
19/12/2025
Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Agreement delivers on President Trump’s four requests, establishing a framework for lower prices for patients in the [...]
Communiqué de presse : Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation
19/12/2025
Sanofi conclut un accord avec le gouvernement américain pour réduire le coût des médicaments et renforcer l’innovation L’accord répond aux quatre demandes du président Trump, établit un cadre pour que les patients [...]
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis
19/12/2025
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi [...]
Galectin Therapeutics Provides Regulatory Update Following FDA Written Response and Announces an Additional $10 Million Line of Credit from Richard E. Uihlein Sufficient to Cover Expected Expenditures Through March 2027
19/12/2025
NORCROSS, Ga., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today [...]
Cue Biopharma Announces Pricing of $10 Million Public Offering
19/12/2025
BOSTON, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
IN8bio Announces Pricing of Private Placement of up to $40.2 Million to Advance Novel Gamma-Delta T Cell Engager
19/12/2025
$20.1 million upfront with a milestone-driven additional $20.1 million to advance INB-619, IN8bio’s novel gamma-delta (“γδ”) T cell engager through an Investigational New Drug (“IND”) application Financing led by [...]
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives
19/12/2025
Total national coverage footprint for PENFS increases to roughly 100 million covered lives CARMEL, Ind., Dec. 19, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical [...]
Glass House Brands Applauds Cannabis Reform Action
19/12/2025
LONG BEACH, Calif. and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the "Company") (CBOE CA: GLAS.A.U) (CBOE CA: GLAS.WT.U) (OTCQX: GLASF) (OTCQX:GHBWF), one of the fastest- [...]
Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy
19/12/2025
MULTI-DAT Framework Drives Diversified Crypto Expansion and Volatility Hedging DALLAS, TX, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (the “Company”), a company focused on developing, [...]
Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
19/12/2025
Avicanna’s evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna’s 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE [...]
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19/12/2025
FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the [...]
Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2
19/12/2025
MSD declines to exercise option for EVX-B2 development Evaxion is now able to out-license EVX-B2 to another partner Evaxion maintains its strong belief in EVX-B2, which has shown to be protective against Gonorrhea in [...]
OKYO Pharma to Ring the Opening Bell at Nasdaq
19/12/2025
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO ), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular [...]
ProPhase Labs Signs Non-Binding LOI for Proposed Reverse Merger with Advanced Biological Laboratories
19/12/2025
Proposed transaction aims to deliver near-term value for ProPhase shareholders, long-term growth for ABL, and create a global, innovation-driven company. Company to hold a virtual conference call today at 10:00 a.m. ET [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum